Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Individuals suffering from conditions like irritable bowel syndrome (IBS), Crohn's disease, ulcers, and leaky gut syndrome may benefit from its reported ability to repair the digestive tract lining
Two items ( Lepr and Foxj1 ) are custom probes
Ulcerative colitis is a type of IBD that affects the colon
Retatrutide (LY3437943) is Eli Lillys experimental triple-agonist drug that activates: GLP-1 (Glucagon-like peptide-1) reduces appetite and slows digestion GIP (Glucose-dependent insulinotropic peptide) enhances insulin sensitivity Glucagon receptor increases fat metabolism and energy expenditure In phase-2 trials, Retatrutide achieved up to 24% body-weight reduction rivaling or even surpassing bariatric surgery outcomes
Storage guidance: Store at controlled room temperature
Supplementary Table 7 (download XLSX Tabulated results of quantified immunohistochemistry sections of the mouse DVC
